TECHNOLOGY

Proprietary technology:

PTM Profiling

cycle-ptm.png

Proteins are the functional units responsible for carrying out all biological processes and control cellular function. The life cycle of proteins is determined
by 3 phases:

Integrating cutting edge solutions with unmet clinical needs:

our unique and proprietary technologies

PTM Biosciences is employing innovative and state-of-the art epiProteomic solutions conceived by Yifat Merbl, PhD, that provide the most relevant information to disease phenotype and pathological state, generating proprietary, novel data for biomarker discovery & therapeutics.

Our edge is tackling different aspects from most of the current personalized medicine approaches, namely the protein modifications (PTM Profiling).
Integrating this unique approach and datasets of the protein modifications, with specific algorithmic and computational tools, provides an unparalleled view on this layer of regulation that is currently not accessible.

 
plate2.png

PTM

PROFILING

Marc Kirschner, PhD

Yifat Merbl, PhD

Harvard Medical School

PTM PROFILING

After a protein is being made it undergoes multiple chemical changes and modifications which are called post-translational modifications (PTM). PTMs determine proteins' function, stability, cellular localization and even their binding partners

science.png

The PTM profiling technology allows high throughput analysis of protein modifications. We analyze liquid biopsies and tissue biopsies of diverse clinical conditions and utilizing Artificial Intelligence, we gain insight into the tissue function and activity, integrating protein modifications into novel targets for biomarker discovery and therapeutics.

 

PRODUCT LINE - PROGNOSTIC KITS

ptm-chip.png

PTM FIT

TM

ptm-bids.png

PTM BEAD

TM

Companion diagnostics
for predicting benefit of drugs

Prognostic kits

for predicting disease progression

PRODUCT LINE - THERAPEUTIC TARGETS

ptm-protesome-product.png

PTM CURE

TM

Novel therapeutic targets for T cell-mediated therapies (e.g. anti-cancer vaccines)

Our technologies are based on scientific publication in leading journals

document.png

Post-translational modification profiling – A novel tool for mapping the protein modification landscape in cancer.
Eisenberg-Lerner A, Ciechanover A, Merbl Y. ​
Experimental Biology and Medicine, 2016 Apr. 241(14):1475-82

document.png

Microarray discovery of new OGT substrates: the medulloblastoma oncogene OTX2 is O-GlcNAcylated. 
Ortiz-Meoz RF, Merbl Y, Kirschner MW, Walker S.
J Am Chem Soc. 2014 Apr 2;136(13):4845-8. doi: 10.1021/ja500451w. Epub 2014 Mar 17.

document.png

Profiling of ubiquitin-like modifications reveals features of mitotic control.
Merbl Y, Refour P, Patel H, Springer M, Kirschner MW.
Cell. 2013 Feb 28;152(5):1160-72. doi: 10.1016/j.cell.2013.02.007.

document.png

Protein microarrays for genome-wide posttranslational modification analysis.
Merbl Y, Kirschner MW.
Wiley Interdiscip Rev Syst Biol Med. 2011 May-Jun;3(3):347-56. doi: 10.1002/wsbm.120. Epub 2010 Sep 23. Review.

document.png

Large-scale detection of ubiquitination substrates using cell extracts and protein microarrays.
Merbl Y, Kirschner MW.
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2543-8. doi: 10.1073/pnas.0812892106. Epub 2009 Jan 30.